As a pharmaceutical manufacturing and exporting company with worldwide fame, we at Weefsel Pharma, are bound to observe and analyse huge medical data in order to understand the ongoing and upcoming dynamics in the world of pharmaceuticals.
Our exclusive R&D team has been able to draw various interesting observations regarding this matter, which also in a way explains why some of the drug categories of our vast catalogue are experiencing ever increasing demand from the international market.
Different Types of Pharmaceutical Drugs with Highest Manufacturing Demand and Profit Margin (as recorded in FY21)
- Cardiac- INR 21,078 Cr.
- Anti-Infectives- INR 18,750 Cr.
- Gastro-Intestinal Tract (GIT)- INR 17,200 Cr.
- Anti-Diabetic- INR 16,060 Cr.
- Vitamins/ Minerals/ Nutrients– INR INR 14,085 Cr.
Cardiac medication or cardiovascular agent medicines are topping the chart of the highest-selling drug therapy by pharma manufacturers in India, over the last decade, while anti-diabetics drugs have catapulted to among the top five highest grossing drug categories in India during this period.
What makes this surge stark is that anti-diabetes drugs were not even among the top-five selling therapies till 2011, and cardiac drugs till the beginning of the millennium.
At around Rs 21,000 crore annually, cardiac medication forms the biggest therapy of drugs being manufactured and exported in bulk in the most recent times; followed by anti-infectives and also the GIT medicines. It is really interesting to observe the change as a decade ago, cardiac medication was a third of its size and the second largest-therapy by sales.
Did you know?
Weefsel Pharma is responsible for manufacturing and exporting multiple types of anti-infectives like antibiotics, antifungals, anthelmintics, antimalarials, antiprotozoals, antituberculosis agents, and antivirals.
At around Rs 16,000 crore, anti-diabetes medication today is the fourth-largest therapy of drugs sold in the country, posting the maximum and an unfortunate surge among the leading therapies.
A long-series data on drug sales over the past three decades processed by a human data science company, demonstrates that the fast emergence of lifestyle disorders related to heart and blood sugar in the recent years, in addition to acute illnesses.
As it is, these drug therapies are fast-moving categories for which people are willing to pay, companies too have interest in coming up with newer molecules where money is to be made.
As per some experts, the pandemic has only accelerated this trend of increasing investment on these fast-moving categories. According to them, the pre-pandemic projections of the incidence of cardio-vascular disorders and diabetes were already high.
The coronavirus Covid-19 only cause acceleration to these projections, considering the genetic predisposition of South Asians to cardiometabolic disorders. The causation of diabetes due to use of steroids in Covid-19 therapy, and the impact of Covid on beta cells in the pancreas are still under rigorous research.
Covid-19 has also been found guilty of triggering new or early onset of diabetes among a certain section of people amid the second wave. Pharma researchers have concluded that with an already high burden of non-communicable diseases, it becomes extremely important to observe the impact of Covid-19 and post-Covid complications on lung health, cardiac and respiratory systems.
Ever Increasing Global Demand for Generics and Expiring Branded Drug Patents
The patents of numerous branded injectables in several parts of the world, are likely to expire in a few years time, creating huge amount of opportunities for the generic manufacturers. As per a recent publication by Business Standard, patented drugs worth US$ 240 billion will lose patents globally in a very short time.
Did you know?
Weefsel Pharma is one of the top globally leading names, when it comes to manufacturing and exporting of generic medicines to more than fifty countries till now. Click here to know more.
The shortage of branded medicines and the expiry of branded drug patents are the two major reasons behind manufacturers of generic injectables, moving towards advanced drug delivery systems, including self-injection devices; apart from tapping regulated markets and exploring other markets to generate perennial revenue streams. Moreover, they are also getting future-ready by maintaining adequate supply chains to prevent vulnerabilities, such as those caused by the COVID-19 outbreak.
Numerical Heads-up
- Generic Injectables Market for Vials Segment to Grow Significantly During 2021-2028.
- Generic Injectables Market is projected to reach US$ 150.65 billion by 2028 from US$ 74.74 billion in 2021 and estimated to grow at a CAGR of 10.5% from 2021 to 2028.
On one hand the market growth of generic injectables is attributed to low R&D, marketing, and manufacturing costs; whereas the ever increasing cases of chronic illnesses of recent times, are expected to prompt and also catalyze the market growth of this segment. However, let’s not forget that critical inspection systems for prefilled injection and supply chain related challenges may hinder the growth too.